To evaluate renal dysfunction after stereotactic ablative body radiotherapy (SABR) for inoperable primary renal cell carcinoma (RCC) using nuclear medicine assessments.
In a prospective clinical trial, patients received single fraction renal SABR (26Gy) for tumours <5cm, or fractionated SABR (3×14Gy) for tumours ⩾5cm.